However, the potentially most important therapeutic implication of our results is the indication that astrocytes are a viable target for AR-mediated adjuvant treatment of demyelinating diseases by alleviating the pathologically increased production of at least some pro-inflammatory mediators. Here, AR is linked to demyelinating disease.